Lonza's FY2025 results exceeded expectations, with EBITDA growth significantly ahead of revenue. Click here to read my latest ...

Goldman Sachs, Jefferies and UBS are mandated to lead the syndicated debt financing for the Lone Star-led CHF2.3 billion buyout of Lonza’s Capsules & Health Ingredients (CHI) business, according to ...

Stephen Fry is nominated to the Lonza Board for his extensive track record in the pharma industry and deep experience in ...

Lonza agreed to provide cGMP manufacturing and technical support for commercial scale production of RION’s Purified Exosome Product™ (PEP) drug substance for late phase clinical supply and beyond.

HOLLYWOOD, Fla.--(BUSINESS WIRE)--StarLIMS has agreed to acquire the MODA ® Platform, a trusted solution for manufacturing quality assurance and control in regulated environments. The transaction is ...

Lonza released its annual report on Tuesday, touting strong profitable growth of CHF 6.5 billion (Swiss Francs) in sales ($8.2 billion) and a core Earnings Before Interest, Taxes, Depreciation, and ...

A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing ...

(Reuters) -Lonza said on Friday Chairman Albert Baehny will step down in May after six years in the job, in a second senior management reshuffle in recent months as the Swiss contract drug ...

(Reuters) -Contract drug manufacturer Lonza said on Monday Chief Executive Pierre-Alain Ruffieux will leave the Swiss company by mutual agreement at the end of the month, weighing on investor ...

Lonza Group announced Monday morning that Pierre-Alain Ruffieux will leave his post as CEO at the end of the month. Ruffieux, a former Roche executive, joined Lonza in 2020 and oversaw the company’s ...